Avozine Dosage/Direction for Use

The tablet must be taken orally, swallowed whole with liquid and may be taken with or without food. It is recommended to take the daily dose in one single intake.
Adults and Adolescents 12 Years and Above: The daily recommended dose is 5mg (1 tablet).
Children Aged 6 to 11 Years: The daily recommended dose is 5mg (1 tablet). It is not recommended for children aged less than 6 years.
Elderly: Adjustment of the dose is recommended in elderly patients with moderate to severe renal impairment (see Patients with Renal Impairment as follows).
Patients with Renal Impairment: The dosing intervals must be individualised according to renal function. Refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient's creatinine clearance (CLcr) in ml/min is needed. The CLcr (ml/min) may be estimated from serum creatinine (mg/dl) determination using the following formula: (See equation.)

Click on icon to see table/diagram/image

Dosing Adjustments for Patients Impaired Renal Function: (See table.)

Click on icon to see table/diagram/image

In paediatric patients suffering from renal impairment, the dose will have to be adjusted on an individual basis taking into account the renal clearance of the patient and his body weight. There is no specific data for children with renal impairment.
No dose adjustment is needed in patients with solely hepatic impairment. In patients with both hepatic impairment and renal impairment, adjustment of the dose is recommended.
Duration of Use: Intermittent allergic rhinitis (symptoms < 4 days/week or during less than 4 weeks) has to be treated according to the disease and its history; it can be stopped once the symptoms have disappeared and can be restarted again when symptoms reappear. In case of persistent allergic rhinitis (symptoms > 4 days/week and during more than 4 weeks), continuous therapy can be proposed to the patient during the period of exposure to allergens. Clinical experience with 5 mg levocetirizine as a film-coated tablet formulation is currently available for a 6-month treatment period. For chronic urticaria and chronic allergic rhinitis, up to one year's clinical experience is available for the racemate cetirizine.